Literature DB >> 20616184

Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease.

David M Good1, Petra Zürbig, Angel Argilés, Hartwig W Bauer, Georg Behrens, Joshua J Coon, Mohammed Dakna, Stéphane Decramer, Christian Delles, Anna F Dominiczak, Jochen H H Ehrich, Frank Eitner, Danilo Fliser, Moritz Frommberger, Arnold Ganser, Mark A Girolami, Igor Golovko, Wilfried Gwinner, Marion Haubitz, Stefan Herget-Rosenthal, Joachim Jankowski, Holger Jahn, George Jerums, Bruce A Julian, Markus Kellmann, Volker Kliem, Walter Kolch, Andrzej S Krolewski, Mario Luppi, Ziad Massy, Michael Melter, Christian Neusüss, Jan Novak, Karlheinz Peter, Kasper Rossing, Harald Rupprecht, Joost P Schanstra, Eric Schiffer, Jens-Uwe Stolzenburg, Lise Tarnow, Dan Theodorescu, Visith Thongboonkerd, Raymond Vanholder, Eva M Weissinger, Harald Mischak, Philippe Schmitt-Kopplin.   

Abstract

Because of its availability, ease of collection, and correlation with physiology and pathology, urine is an attractive source for clinical proteomics/peptidomics. However, the lack of comparable data sets from large cohorts has greatly hindered the development of clinical proteomics. Here, we report the establishment of a reproducible, high resolution method for peptidome analysis of naturally occurring human urinary peptides and proteins, ranging from 800 to 17,000 Da, using samples from 3,600 individuals analyzed by capillary electrophoresis coupled to MS. All processed data were deposited in an Structured Query Language (SQL) database. This database currently contains 5,010 relevant unique urinary peptides that serve as a pool of potential classifiers for diagnosis and monitoring of various diseases. As an example, by using this source of information, we were able to define urinary peptide biomarkers for chronic kidney diseases, allowing diagnosis of these diseases with high accuracy. Application of the chronic kidney disease-specific biomarker set to an independent test cohort in the subsequent replication phase resulted in 85.5% sensitivity and 100% specificity. These results indicate the potential usefulness of capillary electrophoresis coupled to MS for clinical applications in the analysis of naturally occurring urinary peptides.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20616184      PMCID: PMC2984241          DOI: 10.1074/mcp.M110.001917

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  65 in total

1.  Towards defining the urinary proteome using liquid chromatography-tandem mass spectrometry. I. Profiling an unfractionated tryptic digest.

Authors:  C S Spahr; M T Davis; M D McGinley; J H Robinson; E J Bures; J Beierle; J Mort; P L Courchesne; K Chen; R C Wahl; W Yu; R Luethy; S D Patterson
Journal:  Proteomics       Date:  2001-01       Impact factor: 3.984

2.  Exploring the hidden human urinary proteome via ligand library beads.

Authors:  Annalisa Castagna; Daniela Cecconi; Lau Sennels; Juri Rappsilber; Luc Guerrier; Frederic Fortis; Egisto Boschetti; Lee Lomas; Pier Giorgio Righetti
Journal:  J Proteome Res       Date:  2005 Nov-Dec       Impact factor: 4.466

Review 3.  The prospects for "personalized medicine" in drug development and drug therapy.

Authors:  J Woodcock
Journal:  Clin Pharmacol Ther       Date:  2007-02       Impact factor: 6.875

4.  High-resolution proteome/peptidome analysis of peptides and low-molecular-weight proteins in urine.

Authors:  Harald Mischak; Bruce A Julian; Jan Novak
Journal:  Proteomics Clin Appl       Date:  2007-07-10       Impact factor: 3.494

5.  Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in anti-neutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Marion Haubitz; David M Good; Alexander Woywodt; Hermann Haller; Harald Rupprecht; Dan Theodorescu; Mohammed Dakna; Joshua J Coon; Harald Mischak
Journal:  Mol Cell Proteomics       Date:  2009-06-28       Impact factor: 5.911

6.  Serial changes in urinary proteome profile of membranous nephropathy: implications for pathophysiology and biomarker discovery.

Authors:  Heidi Hoi-Yee Ngai; Wai-Hung Sit; Ping-Ping Jiang; Ruo-Jun Xu; Jennifer Man-Fan Wan; Visith Thongboonkerd
Journal:  J Proteome Res       Date:  2006-11       Impact factor: 4.466

Review 7.  Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery.

Authors:  Walter Kolch; Christian Neusüss; Matthias Pelzing; Harald Mischak
Journal:  Mass Spectrom Rev       Date:  2005 Nov-Dec       Impact factor: 10.946

8.  Urinary proteomic biomarkers in coronary artery disease.

Authors:  Lukas U Zimmerli; Eric Schiffer; Petra Zürbig; David M Good; Markus Kellmann; Laetitia Mouls; Andrew R Pitt; Joshua J Coon; Roland E Schmieder; Karlheinz H Peter; Harald Mischak; Walter Kolch; Christian Delles; Anna F Dominiczak
Journal:  Mol Cell Proteomics       Date:  2007-10-19       Impact factor: 5.911

9.  Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis.

Authors:  Stephane Decramer; Stefan Wittke; Harald Mischak; Petra Zürbig; Michael Walden; François Bouissou; Jean-Loup Bascands; Joost P Schanstra
Journal:  Nat Med       Date:  2006-03-19       Impact factor: 53.440

10.  Post-acquisition ETD spectral processing for increased peptide identifications.

Authors:  David M Good; Craig D Wenger; Graeme C McAlister; Dina L Bai; Donald F Hunt; Joshua J Coon
Journal:  J Am Soc Mass Spectrom       Date:  2009-03-14       Impact factor: 3.109

View more
  148 in total

1.  Comparing and combining capillary electrophoresis electrospray ionization mass spectrometry and nano-liquid chromatography electrospray ionization mass spectrometry for the characterization of post-translationally modified histones.

Authors:  Bettina Sarg; Klaus Faserl; Leopold Kremser; Bernhard Halfinger; Roberto Sebastiano; Herbert H Lindner
Journal:  Mol Cell Proteomics       Date:  2013-05-29       Impact factor: 5.911

Review 2.  Biomarkers in IgA nephropathy: relationship to pathogenetic hits.

Authors:  Margaret Colleen Hastings; Zina Moldoveanu; Hitoshi Suzuki; Francois Berthoux; Bruce A Julian; John T Sanders; Matthew B Renfrow; Jan Novak; Robert J Wyatt
Journal:  Expert Opin Med Diagn       Date:  2013-11

Review 3.  Mass spectrometry in chronic kidney disease research.

Authors:  Michael L Merchant
Journal:  Adv Chronic Kidney Dis       Date:  2010-11       Impact factor: 3.620

Review 4.  Proteomic biomarkers in kidney disease: issues in development and implementation.

Authors:  Harald Mischak; Christian Delles; Antonia Vlahou; Raymond Vanholder
Journal:  Nat Rev Nephrol       Date:  2015-02-03       Impact factor: 28.314

5.  Peptidomic Analysis of Urine from Youths with Early Type 1 Diabetes Reveals Novel Bioactivity of Uromodulin Peptides In Vitro.

Authors:  Julie A D Van; Sergi Clotet-Freixas; Joyce Zhou; Ihor Batruch; Chunxiang Sun; Michael Glogauer; Luca Rampoldi; Yesmino Elia; Farid H Mahmud; Etienne Sochett; Eleftherios P Diamandis; James W Scholey; Ana Konvalinka
Journal:  Mol Cell Proteomics       Date:  2019-12-26       Impact factor: 5.911

Review 6.  Proteomics and diabetic nephropathy: what have we learned from a decade of clinical proteomics studies?

Authors:  Massimo Papale; Salvatore Di Paolo; Grazia Vocino; Maria Teresa Rocchetti; Loreto Gesualdo
Journal:  J Nephrol       Date:  2014-02-25       Impact factor: 3.902

7.  Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy.

Authors:  Justyna Siwy; Joost P Schanstra; Angel Argiles; Stephan J L Bakker; Joachim Beige; Petr Boucek; Korbinian Brand; Christian Delles; Flore Duranton; Beatriz Fernandez-Fernandez; Marie-Luise Jankowski; Mohammad Al Khatib; Thomas Kunt; Maria Lajer; Ralf Lichtinghagen; Morten Lindhardt; David M Maahs; Harald Mischak; William Mullen; Gerjan Navis; Marina Noutsou; Alberto Ortiz; Frederik Persson; John R Petrie; Johannes M Roob; Peter Rossing; Piero Ruggenenti; Ivan Rychlik; Andreas L Serra; Janet Snell-Bergeon; Goce Spasovski; Olivera Stojceva-Taneva; Matias Trillini; Heiko von der Leyen; Brigitte M Winklhofer-Roob; Petra Zürbig; Joachim Jankowski
Journal:  Nephrol Dial Transplant       Date:  2014-03-02       Impact factor: 5.992

Review 8.  Early detection of diabetic kidney disease: Present limitations and future perspectives.

Authors:  Chih-Hung Lin; Yi-Cheng Chang; Lee-Ming Chuang
Journal:  World J Diabetes       Date:  2016-07-25

9.  Application of Proteomic Analysis to Renal Disease in the Clinic.

Authors:  Bruce A Julian; Hitoshi Suzuki; Goce Spasovski; Yusuke Suzuki; Yasuhiko Tomino; Jan Novak
Journal:  Proteomics Clin Appl       Date:  2009-01-01       Impact factor: 3.494

10.  Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria.

Authors:  Sten Andersen; Harald Mischak; Petra Zürbig; Hans-Henrik Parving; Peter Rossing
Journal:  BMC Nephrol       Date:  2010-11-01       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.